5 January 2020 - KYE Pharmaceuticals today announced an important milestone, Corzyna (ranolazine extended release tablets) has now been approved by Health Canada after a positive expedited review.

Cozyna is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti-anginal therapies (including beta-blockers and calcium antagonists).

Read KYE Pharmaceuticals press release